Last reviewed · How we verify
Novartis AG — Portfolio Competitive Intelligence Brief
NVS (NYSE)
161 marketed
0 filed
45 Phase 3
22 Phase 2
18 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Vanrafia | ATRASENTAN | marketed | Immunology | 2025-01-01 | ||
| Pluvicto | TETRAXETAN | marketed | Radioligand Therapeutic Agent [EPC] | Oncology | 2025-01-01 | |
| Gallium Oxydatum | GALLIUM | marketed | Glutamate carboxypeptidase 2, Prostate-specific antigen | Urology | 2025-01-01 | |
| Fabhalta | IPTACOPAN | marketed | Factor B | Immunology | 2023-01-01 | |
| Pluvicto | Lutetium (177Lu) vipivotide tetraxetan | marketed | Radioligand Therapeutic Agent [EPC] | Prostate-specific antigen | Oncology | 2022-01-01 |
| Scemblix | ASCIMINIB | marketed | Tyrosine-protein kinase ABL1 | Oncology | 2021-01-01 | |
| Scemblix | ASCIMINIB HYDROCHLORIDE | marketed | ABL1 kinase of BCR::ABL1 | Oncology | 2021-01-01 | |
| Leqvio | INCLISIRAN | marketed | Proprotein convertase subtilisin/kexin type 9 | Metabolic | 2021-01-01 | |
| Tabrecta | CAPMATINIB | marketed | Kinase Inhibitor | Hepatocyte growth factor receptor | Oncology | 2020-01-01 |
| Fluorescite | FLUORESCEIN | marketed | Diagnostic Dye | Cytochrome P450 2C19 | Metabolic | 2020-01-01 |
| Egaten | TRICLABENDAZOLE | marketed | Anthelmintic [EPC] | Transthyretin | Infectious Disease | 2019-01-01 |
| Piqray | alpelisib | marketed | PI3Kα | Oncology | 2019-01-01 |
Therapeutic area mix
- Cardiovascular · 35
- Oncology · 25
- Immunology · 22
- Other · 20
- Metabolic · 13
- Neuroscience · 11
- Respiratory · 9
- Infectious Disease · 8
- Neurology · 7
- Immunology / Infectious Disease · 6
Recent regulatory actions (last 90 days)
- — Promacta · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Ritalin · 8840924 · Formulation · US
- — Sandimmune · 8298568 · Formulation · US
- — Sandimmune · 8298568 · US
- — Kisqali · 8324225 · US
- — Afinitor · 9006224 · Method of Use · US
- — Pluvicto · 11318121 · US
- — Pluvicto · 10406240 · US
- — Tobi · 8869794 · Formulation · US
- — Tegretol · 9629797 · Method of Use · US
- — Tegretol · 9770407 · Formulation · US
- — Tegretol · 9750822 · Formulation · US
- — Tegretol · 8410077 · Formulation · US
- — Tegretol · 7635773 · Formulation · US
- — Sandimmune · 9132071 · Formulation · US
- — Sandimmune · 9132071 · US
- — Kisqali · 9416136 · US
- — Kisqali · 8962630 · US
- — Kisqali · 8685980 · US
- — Tobi · 10207066 · Formulation · US
- — Sandimmune · 8614178 · Formulation · US
- — Sandimmune · 8614178 · US
- — Sandimmune · 8292129 · US
- — Sandimmune · 8292129 · Formulation · US
- — Kisqali · 8415355 · US
- — Kisqali · 9868739 · US
- — Kisqali · 9193732 · US
- — Sandimmune · 8561859 · US
- — Sandimmune · 8561859 · Formulation · US
- — Ritalin · 9072680 · Formulation · US
- — Ritalin · 9089496 · Formulation · US
Competitive overlap (companies sharing drug classes)
- Pfizer · 21 shared drug classes
- · 19 shared drug classes
- Sanofi · 15 shared drug classes
- GlaxoSmithKline · 13 shared drug classes
- Merck Sharp & Dohme LLC · 13 shared drug classes
- AstraZeneca · 9 shared drug classes
- Bayer · 9 shared drug classes
- Takeda · 8 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Novartis AG:
- Novartis AG pipeline updates — RSS
- Novartis AG pipeline updates — Atom
- Novartis AG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Novartis AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novartis. Accessed 2026-05-15.